Skip to search formSkip to main contentSkip to account menu

1 ML ixekizumab 80 MG/ML Prefilled Syringe

Known as: IXEKIZUMAB 80MG/ML INJ,SYR,1ML [VA Product], ixekizumab 80 MG per 1 ML Prefilled Syringe, IXEKIZUMAB 80MG/ML INJ 1ML SYR 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

1 ML ixekizumab 80 MG/ML Prefilled Syringe [Taltz]

Broader (1)

Immunosuppressive Agents
Prefilled Syringeixekizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
O23 Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes
With multiple biologic disease-modifying anti-rheumatic drugs (bDMARDs) available, comparisons are important for treatment… 
2019
2019
FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V…
Background Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease of the axial skeleton, and… 
2019
2019
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study
Psoriasis, a chronic disease usually requires long‐term disease management. 
Review
2019
Review
2019
Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta‐analysis and GRADE evaluation
Twenty per cent of patients with plaque psoriasis also have psoriatic arthritis – a disease affecting joints and entheses… 
2018
2018
Efficacy and safety of continuous every‐2‐week dosing of ixekizumab over 52 weeks in patients with moderate‐to‐severe plaque psoriasis in a randomized phase III trial (IXORA‐P)
Ixekizumab is an interleukin‐17A antagonist approved for treatment of moderate‐to‐severe plaque psoriasis with a recommended 160… 
2017
2017
Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
BACKGROUND: Newer psoriasis treatments can achieve greater levels of efficacy than older systemic therapies; however, current… 
2017
2017
Psoriasis: Ixekizumab reduziert Juckreiz
Für viele Patienten mit einer Psoriasis ist der Juckreiz das schlimmste Symptom. Beim Plaque-Typ sind 60% betroffen mit negativen… 
2017
2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
BackgroundPatients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic… 
2017
2017
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
2016
2016
Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
BACKGROUND Ixekizumab, a monoclonal antibody that selectively targets interleukin-17A, has been established as safe and effective… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)